Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,304 across all filing types
Latest filing 2023-02-10 Major Shareholding Noti…
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
SC 13G/A
Major Shareholding Notification
2023-02-10 English
FINAL RESULTS
Foreign Filer Report
2023-02-09 English
Final Results
Earnings Release Classification · 1% confidence The document text contains key phrases like 'Full year and Q4 2022 results', 'Revenue and EPS summary FY 2022 Q4 2022', detailed financial tables for the full year and Q4, guidance for FY 2023, and commentary from the CEO on performance and pipeline. This structure is characteristic of a comprehensive annual financial results announcement, which typically aligns with the content of a 10-K filing, although this specific document appears to be the press release or earnings release accompanying the 10-K filing. Since the text provides the full, detailed financial performance summary, including margins, expenses, and segment breakdowns, it is more comprehensive than a simple 'Earnings Release' (ER). However, it is not the formal, audited 10-K document itself, but rather the detailed results announcement. Given the options, 'Interim / Quarterly Report' (IR) is for shorter periods, and 'Earnings Release' (ER) is for initial highlights. Because this document is extremely detailed, covers the full year, and includes forward-looking guidance and pipeline updates, it strongly resembles the content typically found in the Management Discussion and Analysis (MDA) section or the core financial narrative preceding the 10-K filing. Since the document is very long (140k chars) and comprehensive, it is not an RPA. It is a detailed financial report summary. The best fit among the provided codes for a comprehensive annual financial summary announcement that isn't the formal 10-K is often the Earnings Release (ER) if it's the primary public announcement, or MDA if it focuses heavily on management commentary. Given the structure heavily focused on 'FY 2022' results, 'Core EPS', and 'Total Revenue' tables, it functions as the primary Earnings Release (ER) or a detailed Management Report (MDA). Since it contains the full financial tables and guidance, MDA is a strong candidate, but ER is the standard code for the initial results announcement. Given the depth, MDA (Management's detailed explanation of financial results, business trends, and outlook) is slightly more appropriate than ER (initial announcement of key highlights only). However, the presence of the RNS Number and the date/time stamp suggests this is the official regulatory announcement of the results, which is often categorized as ER or MDA. I will classify it as ER as it is the primary results announcement, but acknowledge its depth borders on MDA. Q4 2022
2023-02-09 English
SC TO-T/A Filing
Regulatory Filings
2023-02-03 English
TOTAL VOTING RIGHTS
Foreign Filer Report
2023-02-01 English
Total Voting Rights
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is identified by the 'RNS Number' header and explicitly states it is provided by 'RNS, the news service of the London Stock Exchange'. The content details the total number of voting rights and issued share capital as of a specific date (31 January 2023), which is a mandatory disclosure under the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of regulatory update regarding voting rights and capital structure, when issued via the RNS system, fits best under the general 'Regulatory Filings' category (RNS) as it is not a specific financial report (like 10-K or IR) or a specific corporate action announcement (like DIV or SHA). Although it relates to voting rights, it is a routine regulatory disclosure rather than the results of a vote (DVA) or a proxy solicitation (PSI). Given the source and nature, RNS is the most appropriate classification.
2023-02-01 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.